Department of Radiation Oncology, University of California Davis, Sacramento, 95817, USA.
Am J Clin Oncol. 2010 Dec;33(6):591-4. doi: 10.1097/COC.0b013e3181bead63.
PURPOSE/OBJECTIVE(S): Locally advanced squamous cell cancers of the head and neck with bone and cartilage invasion (BCI) traditionally have been treated with resection followed up with radiotherapy or less commonly definitive chemoradiotherapy (CRT). However, it is unclear whether bone or cartilage invasion confers a worse prognosis in comparison with each other.
MATERIALS/METHODS: T4N0-3M0 squamous cell cancers of the head and neck patients underwent CRT or radical resection followed up with postoperative CRT. Oral cavity, oropharynx, laryngeal and hypopharyngeal squamous cell cancers were included. Radiotherapy ranged from 59.4 to 72 Gy. Concurrent chemotherapy was platinum based.
Forty-six patients with BCI were treated. When treated with CRT, 5-year local control was 55% and 43% for BCI, respectively (P = 0.23). Five-year overall survival for these patients was 54% and 29% for BCI, respectively (P = 0.99). When treated with upfront resection, 5-year local control was not significantly different (P = 0.60) nor was 5-year overall survival (P = 0.15).
This study suggests similar outcomes between patients with bone or cartilage invasion treated with upfront CRT or resection followed by CRT. Concurrent CRT may be viable alternative to resection in patients with either bone or cartilage invasion.
传统上,局部晚期头颈部鳞状细胞癌伴骨和软骨侵犯(BCI)采用手术切除后辅以放疗或较少采用的根治性放化疗(CRT)治疗。然而,目前尚不清楚与其他因素相比,骨或软骨侵犯是否会导致更差的预后。
接受 CRT 或根治性切除术后行术后 CRT 的 T4N0-3M0 头颈部鳞状细胞癌患者。包括口腔、口咽、喉和下咽鳞状细胞癌。放疗范围为 59.4 至 72Gy。同期化疗采用铂类药物。
46 例 BCI 患者接受了治疗。接受 CRT 治疗时,BCI 的 5 年局部控制率分别为 55%和 43%(P=0.23)。这些患者的 5 年总生存率分别为 54%和 29%(P=0.99)。行根治性切除术治疗时,5 年局部控制率无显著差异(P=0.60),5 年总生存率也无显著差异(P=0.15)。
本研究表明,接受 upfront CRT 或根治性切除术后 CRT 治疗的骨或软骨侵犯患者的预后相似。对于有骨或软骨侵犯的患者,同期 CRT 可能是手术切除的可行替代方案。